{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:58:04Z","timestamp":1771261084194,"version":"3.50.1"},"reference-count":46,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The use of anti-thymocyte globulin (ATG) as part of conditioning to prevent graft-versus-host disease (GVHD) may severely impair immune reconstitution (IR). We analyzed relationships between ATG exposure, the recipient lymphocyte count, IR, and transplant outcome. We retrospectively reviewed patients aged \u2264 18 years who underwent allogeneic HSCT between April 2005 and April 2020. The outcomes of interest included the incidence of GVHD, overall survival (OS), and IR. IR was analyzed through thymic magnetic resonance imaging (MRI) and by quantifying T CD4+ and recent thymic emigrants (RTEs). The ATG-exposed group was split into a low ATG\/lymphocyte ratio subgroup (ratio &lt; 0.01) and a high ATG\/lymphocyte ratio subgroup (ratio &gt; 0.01). The low ratio subgroup had a higher incidence of GVHD (29 [59%] vs. 7 [16.6%]) but a better IR in both laboratory and MRI imaging assessments (p &lt; 0.0001). The median thymic volume in the low ratio subgroup was significantly higher (14.7 cm3 vs. 4.5 cm3, p &lt; 0.001). This was associated with a better OS and lower transplant-related mortality (TRM) (80.4% vs. 58.0%, p = 0.031) and (13.1% vs. 33.0%, p = 0.035). An individualized approach to ATG dosing allows for the obtainment of rapid thymic reconstitution and the best transplant-related outcomes.<\/jats:p>","DOI":"10.3390\/jcm12020730","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T03:41:52Z","timestamp":1673926912000},"page":"730","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pre-Transplant Total Lymphocyte Count Determines Anti-Thymocyte Globulin Exposure, Modifying Graft-versus-Host Disease Incidence and Post-Transplant Thymic Restoration: A Single-Center Retrospective Study"],"prefix":"10.3390","volume":"12","author":[{"given":"Antonio Giacomo","family":"Grasso","sequence":"first","affiliation":[{"name":"Institute for Maternal and Child Health\u2014IRCCS Burlo Garofolo, Via dell\u2019Istria 65\/1, 34137 Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9776-3818","authenticated-orcid":false,"given":"Roberto","family":"Simeone","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, ASUGI, Piazza dell\u2019Ospitale 1, 34125 Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Maestro","sequence":"additional","affiliation":[{"name":"Institute for Maternal and Child Health\u2014IRCCS Burlo Garofolo, Via dell\u2019Istria 65\/1, 34137 Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1350-0509","authenticated-orcid":false,"given":"Davide","family":"Zanon","sequence":"additional","affiliation":[{"name":"Institute for Maternal and Child Health\u2014IRCCS Burlo Garofolo, Via dell\u2019Istria 65\/1, 34137 Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0934-1875","authenticated-orcid":false,"given":"Natalia","family":"Maximova","sequence":"additional","affiliation":[{"name":"Institute for Maternal and Child Health\u2014IRCCS Burlo Garofolo, Via dell\u2019Istria 65\/1, 34137 Trieste, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Zaucha-Prazmo, A., Gozdzik, J., Debski, R., Drabko, K., Sadurska, E., and Kowalczyk, J. (2018). Transplant-related mortality and survival in children with malignancies treated with allogeneic hematopoietic stem cell transplantation. A multicenter analysis. Pediatr. Transplant., 22.","DOI":"10.1111\/petr.13158"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-Host Disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/bmt.2011.41","article-title":"Prognostic value of response after upfront therapy for acute GVHD","volume":"47","author":"Saliba","year":"2012","journal-title":"Bone Marrow Transplant."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s12185-015-1785-1","article-title":"State-of-the-art acute and chronic GVHD treatment","volume":"101","author":"Jamil","year":"2015","journal-title":"Int. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/bmt.2013.59","article-title":"Prognosis of grade 3\u20134 acute GVHD continues to be dismal","volume":"48","author":"Jamani","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jiac.2016.05.006","article-title":"An overview of infectious complications after allogeneic hematopoietic stem cell transplantation","volume":"22","author":"Sahin","year":"2016","journal-title":"J. Infect. Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","article-title":"Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti\u2013T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease\u2013Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation","volume":"35","author":"Soiffer","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial","volume":"17","author":"Walker","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.bmt.1704758","article-title":"Antilymphocyte\/thymocyte globulin for graft versus host disease prophylaxis: Efficacy and side effects","volume":"35","author":"Bacigalupo","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1182\/blood.V98.10.2942","article-title":"Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO)","volume":"98","author":"Bacigalupo","year":"2001","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease","volume":"374","author":"Solano","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3109\/14653249.2012.715243","article-title":"Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation","volume":"14","author":"Bosch","year":"2012","journal-title":"Cytotherapy"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.critrevonc.2013.03.009","article-title":"Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis\u2014A systematic review and meta-analysis","volume":"88","author":"Theurich","year":"2013","journal-title":"Crit. Rev. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bbmt.2010.02.027","article-title":"High Rabbit-Antihuman Thymocyte Globulin Levels Are Associated with Low Likelihood of Graft-vs-Host Disease and High Likelihood of Posttransplant Lymphoproliferative Disorder","volume":"16","author":"Podgorny","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(17)30417-5","article-title":"Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: A multicentre, randomised, open-label, phase 3 trial","volume":"18","author":"Locatelli","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.bbmt.2016.01.002","article-title":"Antithymocyte Globulin at Clinically Relevant Concentrations Kills Leukemic Blasts","volume":"22","author":"Dabas","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40262-014-0214-6","article-title":"Population pharmacokinetic modeling of thymoglobulin\u00ae in children receiving allogeneic-hematopoietic cell transplantation: Towards improved survival through individualized dosing","volume":"54","author":"Admiraal","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bbmt.2008.11.027","article-title":"Total and Active Rabbit Antithymocyte Globulin (rATG; Thymoglobulin) Pharmacokinetics in Pediatric Patients Undergoing Unrelated Donor Bone Marrow Transplantation","volume":"15","author":"Call","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood-2016-06-721936","article-title":"Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation","volume":"128","author":"Admiraal","year":"2016","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(15)00045-9","article-title":"Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: A multicentre, retrospective pharmacodynamic cohort analysis","volume":"2","author":"Admiraal","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00281-020-00828-7","article-title":"The role of the thymus in allogeneic bone marrow transplantation and the recovery of the peripheral T-cell compartment","volume":"43","author":"Velardi","year":"2021","journal-title":"Semin. Immunopathol."},{"key":"ref_22","first-page":"151","article-title":"Thymic activity in immune recovery after allogeneic hematopoietic stem cell transplantation in children","volume":"44","author":"Rybka","year":"2020","journal-title":"Central Eur. J. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1007\/s12325-017-0534-7","article-title":"Comparison of Efficacy and Safety of Caspofungin versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis","volume":"34","author":"Maximova","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1182\/blood.V87.5.2082.2082","article-title":"Marrow transplantation for patients with thalassemia: Results in class 3 patients","volume":"87","author":"Lucarelli","year":"1996","journal-title":"Blood"},{"key":"ref_26","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/bbmt.2003.50026","article-title":"Chronic graft-versus-host disease","volume":"9","author":"Lee","year":"2003","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S2352-3026(17)30029-7","article-title":"Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: A multicentre, retrospective, pharmacodynamic cohort analysis","volume":"4","author":"Admiraal","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbmt.2017.08.029","article-title":"Optimizing Antithymocyte Globulin Dosing for Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Based on Recipient Absolute Lymphocyte Count","volume":"24","author":"Kennedy","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaci.2016.02.036","article-title":"Antithymocyte globulin: Importance of good clinical pharmacological practice","volume":"138","author":"Admiraal","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/01.mph.0000184575.00717.25","article-title":"Antithymocyte globulin pharmacokinetics in pediatric patients after hematopoietic stem cell transplantation","volume":"27","author":"Seidel","year":"2005","journal-title":"J. Pediatr. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bbmt.2018.12.065","article-title":"Rabbit Antithymocyte Globulin Serum Levels: Factors Impacting the Levels and Clinical Outcomes Impacted by the Levels","volume":"25","author":"Jamani","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.bbmt.2019.02.021","article-title":"Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation","volume":"25","author":"Scordo","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood-2008-07-163238","article-title":"Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: Analysis of risk factors","volume":"113","author":"MacMillan","year":"2009","journal-title":"Blood"},{"key":"ref_35","first-page":"303","article-title":"Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin","volume":"111","author":"Finke","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/bmt.2013.143","article-title":"Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation","volume":"49","author":"Wolschke","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Bryant, A., Mallick, R., Huebsch, L.B., Allan, D.S., Atkins, H., Anstee, G., Bence-Bruckler, I., Hamelin, L., Hodgins, M., and Sabloff, M. (2016). Low-Dose Anti-Thymocyte Globulin for Graft-Versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplant. Blood, 128.","DOI":"10.1182\/blood.V128.22.5782.5782"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: A randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"E368","DOI":"10.1111\/ctr.12131","article-title":"A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors","volume":"27","author":"Remberger","year":"2013","journal-title":"Clin. Transplant."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1182\/blood-2011-01-329821","article-title":"Chronic graft-versus-host disease: Long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti\u2013T-cell globulin ATG-Fresenius","volume":"117","author":"Schmoor","year":"2011","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.bmt.1703530","article-title":"In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-vs-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors","volume":"29","author":"Zabelina","year":"2002","journal-title":"Bone Marrow Transplant."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00281-008-0132-5","article-title":"Reconstitution of the immune system after hematopoietic stem cell transplantation in humans","volume":"30","author":"Storek","year":"2008","journal-title":"Semin. Immunopathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood.V97.5.1458","article-title":"Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation","volume":"97","author":"Weinberg","year":"2001","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1399-0039.2011.01820.x","article-title":"Thymus and immune reconstitution after allogeneic hematopoietic stem cell transplantation in humans: Never say never again","volume":"79","author":"Toubert","year":"2012","journal-title":"Tissue Antigens"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6768","DOI":"10.1182\/blood-2011-02-334623","article-title":"Thymic T-cell development in allogeneic stem cell transplantation","volume":"117","author":"Krenger","year":"2011","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1097\/TP.0000000000002799","article-title":"Cytotoxic Effects of Rabbit Anti-thymocyte Globulin Preparations on Primary Human Thymic Epithelial Cells","volume":"103","author":"Kaebisch","year":"2019","journal-title":"Transplantation"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/2\/730\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:07:41Z","timestamp":1760119661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/2\/730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,16]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["jcm12020730"],"URL":"https:\/\/doi.org\/10.3390\/jcm12020730","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,16]]}}}